Vaccinex, Inc. (VCNX) financial statements (2021 and earlier)

Company profile

Business Address 1895 MOUNT HOPE AVE
ROCHESTER, NY 14620
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
3/31/2019
Q1
12/31/2018
Q4
9/30/2018
Q3
6/30/2018
Q2
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments3951120271
Cash and cash equivalents39596111
Short-term investments   21416 
Receivables1111100
Other undisclosed current assets0101121
Total current assets:41071321292
Noncurrent Assets
Property, plant and equipment1111111
Other undisclosed noncurrent assets      2
Total noncurrent assets:1111112
TOTAL ASSETS:51171322305
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities77107767
Accounts payable3252224
Accrued liabilities4545444
Due to related parties      1
Other undisclosed current liabilities     00
Total current liabilities:77107769
Noncurrent Liabilities
Liabilities, other than long-term debt      0
Derivative instruments and hedges, liabilities      0
Total noncurrent liabilities:      0
Total liabilities:77107769
Temporary equity, carrying amount      112
Stockholders' equity
Stockholders' equity attributable to parent(26)(20)(26)(18)(9)(0)(140)
Preferred stock      8
Common stock000000 
Treasury stock, value(0)(0)(0)(0)(0)(0)(0)
Additional paid in capital22222220820820820854
Accumulated deficit(249)(242)(235)(226)(217)(208)(202)
Stockholders' equity attributable to noncontrolling interest24242424242424
Total stockholders' equity:(2)4(2)61524(116)
TOTAL LIABILITIES AND EQUITY:51171322305

Income statement (P&L) ($ in millions)

12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
3/31/2019
Q1
12/31/2018
Q4
9/30/2018
Q3
6/30/2018
Q2
Revenues 000000
Cost of revenue (0)(0)(0)(0)(0)(0)
Gross profit: 00(0)(0)(0)(0)
Operating expenses(6)(8)(9)(9)(8)(6)(6)
Operating loss:(6)(8)(9)(9)(9)(6)(7)
Nonoperating income
(Other Nonoperating income)
000000 
Interest and debt expense     (0)(0)
Loss from continuing operations before equity method investments, income taxes:(6)(8)(9)(9)(8)(7)(7)
Other undisclosed income from continuing operations before income taxes     00
Net loss available to common stockholders, diluted:(6)(8)(9)(9)(8)(7)(7)

Comprehensive Income ($ in millions)

12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
3/31/2019
Q1
12/31/2018
Q4
9/30/2018
Q3
6/30/2018
Q2
Net loss:(6)(8)(9)(9)(8)(7)(7)
Comprehensive loss, net of tax, attributable to parent:(6)(8)(9)(9)(8)(7)(7)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: